Wellington Management Group LLP Sells 56,107 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Wellington Management Group LLP decreased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 15.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 309,651 shares of the biopharmaceutical company’s stock after selling 56,107 shares during the period. Wellington Management Group LLP’s holdings in Vanda Pharmaceuticals were worth $1,452,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Meeder Asset Management Inc. bought a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at $39,000. ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at about $40,000. China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth about $61,000. Finally, XTX Topco Ltd bought a new position in Vanda Pharmaceuticals in the 2nd quarter valued at about $75,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on VNDA shares. HC Wainwright started coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 price objective for the company. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Thursday. They set a “hold” rating for the company.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock opened at $4.55 on Thursday. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.46 and a fifty-two week high of $6.75. The firm’s 50-day simple moving average is $4.85 and its 200 day simple moving average is $5.22. The stock has a market cap of $265.30 million, a PE ratio of -16.25 and a beta of 0.76.

Insider Transactions at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 8.90% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.